Drug recall
Market withdrawal of Ukoniq tabletsPharmacy news
Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.
Pharmacy news bulletins available on the portal
For a list of pharmacy news bulletins, pharmacists may sign in to the
Notifications and preauthorizations
Drug recalls
Additional notifications
Information about the launch of generic Flovent HFA
Effective May 28, 2022, generic Flovent HFA (fluticasone propionate) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Flovent HFA will continue to be covered and can be filled for patients.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Breo Ellipta
Effective May 28, 2022, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans (excluding Value prescription drug plan). Brand-name Breo Ellipta will continue to be covered and can be filled for patients.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Dexilant
Effective April 1, 2022, generic Dexilant (dexlansoprazole) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Dexilant will continue to be covered and can be filled for patients.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Restasis
Effective Feb. 12, 2022, generic Restasis (cyclosporine) is not covered or may require prior authorization on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Restasis will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Combigan
Effective Jan. 22, 2022, generic Combigan (brimonidine-timolol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Combigan will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the use of ivermectin and COVID-19
The Centers for Disease Control and Prevention has released a health advisory regarding the rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of products containing ivermectin to prevent and treat COVID-19.
Please see this
Information about the launch of generic Copaxone
Effective Jan. 1, 2022, generic Copaxone (glatiramer acetate) is not covered under Humana’s Basic and Walmart Value Part D plans. Brand-name Copaxone will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this medication may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Updates could mean new requirements for Humana members
Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.
These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.
Information about the launch of generic Durezol
Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Mitigare
Effective Jan. 1, 2021, generic Mitigare (colchicine capsule) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug, Medicare Part D and commercial (including RxAdvantage) plans; brand Mitigare will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Vascepa
Effective Nov. 7, 2020, generic Vascepa (icosapent) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Vascepa will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Tykerb
Effective Oct. 3, 2020, generic Tykerb (lapatinib) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Tykerb will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Symbicort HFA inhaler
Effective Jan. 11, 2020, generic Symbicort HFA inhaler (budesonide/formoterol HFA inhaler) is not covered or may require prior authorization for Medicare and commercial patients; brand Symbicort HFA inhaler will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of authorized generic insulin aspart and insulin aspart mix
Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Afinitor
Effective Dec. 14, 2019, generic Afinitor (everolimus) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Afinitor will continue to be covered with prior authorization and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Med-Edit update notification
As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.